Testing a new medication combined with chemotherapy for colorectal cancer spread to the liver

Plain-English translation of NCT06848842 on ClinicalTrials.gov ↗ · Source last updated October 2025 · Translation generated June 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This clinical trial is testing whether ivonescimab, a new immune-boosting medication, works better when combined with standard chemotherapy for colorectal cancer that has spread to the liver. Right now, if cancer spreads to the liver in a way that surgeons cannot remove it completely, treatment options are limited. This study wants to learn if adding this medication to chemotherapy can shrink the tumors and help more people become candidates for surgery.

Colorectal cancer that spreads to the liver is serious and difficult to treat surgically when the tumors are too large or spread out. Researchers believe that this medication might help the body's immune system fight the cancer more effectively when paired with chemotherapy, potentially making surgery possible for more patients.

Do you qualify?

You likely qualify if…

you are 18 years of age or older
you have been diagnosed with colorectal cancer that has spread to your liver only (with no or minimal spread elsewhere)
your liver tumors have been determined by your medical team to be unresectable (unable to be surgically removed) or borderline resectable
you have not received prior chemotherapy for your metastatic cancer, or if you did receive chemotherapy as initial treatment, it was at least 6 months before your cancer returned
you are in good enough overall health to tolerate the treatment (your doctor confirms your heart, kidneys, liver, and blood counts are adequate)
your primary colorectal tumor can be removed by surgery or has already been removed

You likely don't qualify if…

you have cancer that has spread to organs or areas outside your liver
you have had severe allergic reactions to other monoclonal antibody medications
you have an active autoimmune disease that requires ongoing treatment
you have uncontrolled high blood pressure or have had a major heart event in the past 12 months
you are pregnant, breastfeeding, or have had another cancer diagnosis in the past 5 years

What participation looks like

You would receive the medication and chemotherapy infusions together every 3 weeks, with a planned maximum of 8 treatment cycles (about 6 months of active treatment). You would visit the clinic every 2 cycles (roughly every 6 weeks) for check-ups, blood tests, and imaging scans to see how the tumors are responding. After your treatment ends, your medical team will decide whether you're a candidate for surgery to remove remaining tumors, if you need ongoing maintenance therapy, or if you should stop the study treatment.

AI-generated summary from trial data · Jun 30, 2026 · Not medical advice

Trial locations(1 site)

China

National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing